Skip to main content
. 2017 Mar 21;8(22):35946–35961. doi: 10.18632/oncotarget.16412

Table 1. Tumor incidence (%) for pBABE and IL-8 cl19 8505c xenotransplants treated or not with Reparixin.

Tumor Incidence (%)
Vehicle Reparixin
8505c pBABE 66,7 10*
8505c IL-8 Cl19 90 50*

* P < 0.05 compared to the relative vehicle-treated group of mice.